Page 2 - Nasdaq Vxrt News Today

At the end of the latest market close, Vaxart Inc. (VXRT) was valued at $1.82. In that particular session, Stock kicked-off at the price of $1.92 while reaching the peak value of $1.9245 and lowest value recorded on the day was $1.80. The stock current value is $1.88.Recently in News on October 10,

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief...

Dr. Stapleton has more than 20 years of industry experience leading technical, quality and manufacturing operations at commercial and clinical stage...

Dr. Heron brings decades of experience in executive leadership and life sciences research and development to Vaxart's Board...

Top-line data from COVID-19 Phase II study expected in the third quarter of 2022 Vaxart initiates work on vaccine candidates that directly target new...

Vaxart (NASDAQ:VXRT – Get Rating) and Surface Oncology (NASDAQ:SURF – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends. Risk & Volatility Vaxart has a beta of 0.67, indicating […]

Equities research analysts predict that Vaxart, Inc. (NASDAQ:VXRT – Get Rating) will post sales of $100,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Vaxart’s earnings, with the lowest sales estimate coming in at $90,000.00 and the highest estimate coming in at $100,000.00. Vaxart reported sales of $110,000.00 […]

Wall Street brokerages predict that Vaxart, Inc. (NASDAQ:VXRT – Get Rating) will report ($0.20) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Vaxart’s earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.22). Vaxart posted earnings per share […]

A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in...

Vaxart (NASDAQ:VXRT – Get Rating) and Relay Therapeutics (NASDAQ:RLAY – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Volatility and Risk Vaxart has a beta of 0.41, indicating that […]